BMS - Autoimmune Disease Drugs Business is a technology company.
BMS - Autoimmune Disease Drugs Business has raised $300.0M across 1 funding round.
BMS - Autoimmune Disease Drugs Business has raised $300.0M in total across 1 funding round.
Bristol Myers Squibb (BMS), a global biopharmaceutical company, maintains a significant presence in autoimmune disease treatments through approved products like Orencia (abatacept) for rheumatoid arthritis and Sotyktu (deucravacitinib) for plaque psoriasis, while strategically spinning out early-stage assets to specialized biotechs.[3][8] In July 2025, BMS launched an unnamed startup backed by $300 million from Bain Capital, transferring five immunology assets—including Phase 2 afimetoran (TLR7/8 inhibitor) for systemic lupus erythematosus (SLE), oral TYK2 inhibitor BMS-986322 for plaque psoriasis, IL-2 fusion protein BMS-986326 for SLE and atopic dermatitis, and two Phase 1-ready biologics targeting IL18 and IL10—to focus on unmet needs in autoimmune disorders.[1][2][9] This spinout allows BMS to sharpen its portfolio on high-potential leaders like Sotyktu, while the new entity advances these promising therapies for patients with limited options, with BMS retaining nearly 20% equity, royalties, and milestones.[2]
The autoimmune drugs business addresses immune-mediated conditions affecting millions, serving patients with SLE, psoriasis, atopic dermatitis, and more by developing oral small molecules and biologics that modulate inflammatory pathways like TYK2, TLR7/8, IL-2, IL18, and IL10.[1][2] Growth momentum stems from BMS's broader strategy to generate $3.5 billion in value by 2027 via asset optimization, including this spinout amid layoffs and a pivot to core strengths in oncology, immunology, and cell therapy.[1][2]
BMS traces its roots to 1887 as a merger of Bristol-Myers and Squibb, evolving into a biopharma leader with a legacy in immunology, including Orencia's 2005 approval for rheumatoid arthritis and Sotyktu's 2022 launch as a first-in-class TYK2 inhibitor.[3][4] The autoimmune push intensified post-2019 Celgene acquisition, bolstering its immunology pipeline, but strategic shifts emerged in 2024-2025 amid patent cliffs and R&D reprioritization.[1][3] Pivotal moments include discontinuing BMS-986322 in February 2025 to prioritize Sotyktu commercialization, as stated by Chief Medical Officer Samit Hirawat, and the July 2025 spinout announcement partnering with Bain Capital.[1][2]
This unnamed biotech emerged directly from BMS's July 2025 deal, in-licensing the five assets with Bain's $300 million lead investment following their $3 billion life sciences fund close.[1][9] BMS Chief Research Officer Robert Plenge, M.D., Ph.D., joins the board, ensuring continuity, while Senior VP Julie Rozenblyum highlighted the assets' "significant potential" for patient impact.[2][9] It builds on BMS's history of spinouts, like 2020's Anteros Pharmaceuticals for inflammation therapies.[3]
BMS's autoimmune efforts ride the wave of precision immunology, fueled by TYK2 and IL pathway breakthroughs that expand beyond steroids and biologics to oral options, amid a market projected to grow as autoimmune prevalence rises with aging populations and diagnostics.[1][2][6] Timing aligns with BMS's 2025-2027 value creation goal ($3.5B target), using spinouts to monetize non-core assets while Bain's life sciences push (post-$3B fund, Mitsubishi Tanabe acquisition) accelerates biotech innovation.[1] Market forces favor this: post-COVID autoimmune flares, SLE's orphan status, and competition from AbbVie, Roche, but BMS's track record (e.g., Sotyktu success) influences ecosystems by seeding independents that could yield royalties or reacquisitions.[2][3]
The spinout exemplifies biopharma's "portfolio pruning" trend, offloading Phase 1-2 assets to nimble players, enhancing overall efficiency and patient access in a $100B+ immunology space.[1][9]
The unnamed Bain-BMS spinout is poised to nominate clinical candidates by 2026-2027, potentially delivering first Phase 3 data from afimetoran or BMS-986322 by 2028, capitalizing on TYK2/IL momentum amid rising autoimmune trial activity.[1][2] Trends like in vivo CAR-T (e.g., BMS's Orbital acquisition for B-cell reset in autoimmunity) and AI-driven target ID will shape its path, possibly expanding to fibrosis or oncology.[5][6] BMS's influence may evolve through equity upside and pipeline refills, reinforcing its immunology leadership while the startup pioneers oral therapies, ultimately tying back to transforming patient lives through bold science.[4][9]
BMS - Autoimmune Disease Drugs Business has raised $300.0M in total across 1 funding round.
BMS - Autoimmune Disease Drugs Business's investors include Bain Capital, Bain Capital Life Sciences.
BMS - Autoimmune Disease Drugs Business has raised $300.0M across 1 funding round. Most recently, it raised $300.0M BMS - Series A in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $300.0M BMS - Series A | Bain Capital, Bain Capital Life Sciences |